Trial Profile

A Phase 1b Randomized, Double-Blinded, Placebo Controlled, Multi-Cohort Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenacapavir (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide
Indications HIV-1 infections
Focus Proof of concept; Therapeutic Use
Sponsors Gilead Sciences

Most Recent Events

13 Jan 2022 Results published in the Journal of Antimicrobial Chemotherapy
08 Oct 2020 Results of resistance analysis presented at the 15th International Congress on Drug Therapy and HIV Infection
30 Sep 2020 According to a Gilead Sciences media release, data from this study will pe presented at the HIV Glasgow 2020 conference.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com